Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: The ASSIST-K study

Takai, Masahiko; Ishikawa, Masashi; Maeda, Hitoshi; Kanamori, Akira; Kubota, Akira; Amemiya, Hikaru; Iizuka, Takashi; Iemitsu, Kotaro; Iwasaki, Tomoyuki; Uehara, Goro; Umezawa, Shinichi; Obana, Mitsuo; Kaneshige, Hideaki; Kaneshiro, Mizuki; Kawata, Takehiro; Sasai, Nobuo; Saito, Tatsuya; Takuma, Tetsuo; Takeda, Hiroshi; Tanaka, Keiji; Tsurui, Nobuaki; Nakajima, Shigeru; Hoshino, Kazuhiko; Honda, Shinichi; Machimura, Hideo; Matoba, Kiyokazu; Minagawa, Fuyuki; Minami, Nobuaki; Miyairi, Yukiko; Mokubo, Atsuko; Motomiya, Tetsuya; Waseda, Manabu; Miyakawa, Masaaki; Naka, Yoshifumi; Terauchi, Yasuo; Tanaka, Yasushi; Matsuba, Ikuro

doi:10.1016/j.diabres.2013.12.045

Cited by 13 publications

(16 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In many studies, sitagliptin reportedly improved HbA1c and fasting blood glucose levels both as a single-drug therapy [3, 8–10] and as a combination therapy with other antidiabetic drugs [4, 5, 11]. In our study, we excluded patients undergoing insulin use, also some clinical trials [12, 13] reported about the combination therapy about sitagliptin and insulin. The patients in the present study had chronic diabetes mellitus, and many had already been inadequately controlled with antidiabetic drugs and additionally received sitagliptin.…”

Section: Discussionmentioning

confidence: 99%

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study

et al. 2016

View full text Add to dashboard Cite

BackgroundTo investigate the ameliorating effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood glucose control in patients with type 2 diabetes mellitus who were previously untreated with or who have a poor responsive to existing antidiabetic drugs.MethodsSitagliptin (50 mg/day) was added on to the pre-existing therapy for type 2 diabetes and changes in the glycated hemoglobin (HbA1c) level after 3 months of treatment were compared with the baseline and performed exploratory analysis.ResultsHbA1c levels were significantly decreased after 1 month of treatment compared to baseline, with a mean change in HbA1c level from baseline of −0.73% (range, −0.80 to −0.67) in the entire study population at 3 months. Patients who received a medium dose of glimepiride showed the least improvement in HbA1c levels. The percentage of patients who achieved an HbA1c level of <7.0% significantly increased after 1 month of treatment, reaching 53.1% at 3 months. The percentage of patients who achieved a fasting blood glucose level of <130 mg/dL significantly increased after 1 month of treatment, reaching 50.9% at 3 months.ConclusionsSitagliptin improved the HbA1c level and rate of achieving the target control levels in patients with type 2 diabetes mellitus who were previously untreated with, or poorly responsive to, existing antidiabetic drugs. Thus, sitagliptin is expected to be useful in this patient group. However, the additional administration of sitagliptin in patients treated with medium-dose glimepiride only slightly improved blood glucose control when corrected for baseline HbA1c level.Electronic supplementary materialThe online version of this article (doi:10.1186/s12902-016-0149-z) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…21,22 Based on the results of previous studies, liraglutide was expected to reduce fasting and postprandial glucose levels. 20,23 In addition, we added sitagliptin to the detemir group to improve postprandial glucose levels in this study based on previous reports of the efficacy and safety of insulin therapy plus sitagliptin, 14,24 mainly by improving postprandial glucose levels. Insulin therapy is associated with weight gain.…”

Section: Discussionmentioning

confidence: 99%

“…The GLP‐1 receptor agonist, especially liraglutide, improves postprandial glycemic control and reduces body weight without increasing the risk of severe hypoglycemia in patients with type 2 diabetes . Adding a DPP‐4 inhibitor to insulin therapy is also useful in glycemic control without causing severe hypoglycemia, especially for long‐acting and once‐daily insulin regimens …”

mentioning

confidence: 99%

“…12,13 Adding a DPP-4 inhibitor to insulin therapy is also useful in glycemic control without causing severe hypoglycemia, especially for long-acting and once-daily insulin regimens. 14 However, there are no prospective studies assessing the effectiveness of switching from a basal-bolus insulin regimen to once-daily injection. Therefore, in this study, we compared the efficacy, safety, and patient satisfaction with liraglutide versus insulin detemir plus sitagliptin.…”

mentioning

confidence: 99%

See 1 more Smart Citation

A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once‐daily injection in patients with well‐controlled type 2 diabetes

Inoue

Nakamura

Kondo

et al. 2015

The Journal of Clinical Pharma

Self Cite

View full text Add to dashboard Cite

This study aimed to compare the efficacy and safety of liraglutide versus insulin detemir plus sitagliptin in Japanese patients with type 2 diabetes treated with a basal-bolus insulin regimen. In this multicenter, open-label trial, 90 patients whose diabetes had been controlled well or moderately (glycated hemoglobin [HbA1c ] ≤ 7.3%) with basal-bolus insulin regimen were randomly assigned to a liraglutide group or a detemir group and were followed up for 24 weeks. The primary end point was HbA1c change from baseline to 24 weeks. Of the 90 enrolled patients, 82 completed this trial. At 24 weeks, the mean changes in HbA1c from baseline were 0.1% ± 0.9% versus 0.3% ± 0.8% in the liraglutide versus detemir groups, respectively (P = .46). The "overall" satisfaction score for the Diabetes Treatment Satisfaction Questionnaire changed from 25.2 ± 7.4 to 29.9 ± 5.3 (P < .001) and from 26.4 ± 6.1 to 28.3 ± 6.4 (P = .12) in the liraglutide and detemir groups, respectively. Although the mean change difference in HbA1c between both groups was not significant, switching from a basal-bolus insulin regimen to liraglutide once daily improved patient satisfaction levels without loss of glycemic control.

show abstract

“…Despite differences in their metabolism and recommended daily dosage, the different DPP‐4 inhibitors are similar in efficacy, safety profile, and patient tolerance . Trials of DPP‐4 inhibitors added to basal insulin in patients with suboptimal glycemic control generally showed greater declines in HbA1c, PPG, and FPG compared with placebo, with no difference in effect on weight or weight loss, and a similar rate of hypoglycemia (Table ) …”

Section: Dipeptidyl Peptidase‐4 Inhibitorsmentioning

confidence: 99%

Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies

Umpiérrez

Bailey

Carcia

et al. 2017

Journal of Diabetes

View full text Add to dashboard Cite

A large number of patients with type 2 diabetes (T2D) on basal insulin do not reach their HbA1c goals and require additional therapy to address postprandial hyperglycemia. Guidelines from expert bodies have outlined several approaches to accomplish postprandial glucose (PPG) control, and recent literature suggests several more. This article provides strategies for primary care physicians caring for patients with T2D who do not achieve glycemic control with basal insulin alone. Current treatment guidelines and strategies for improving PPG control are reviewed, including the efficacy, safety, and cost-effectiveness of rapid-acting insulin (RAI) analogs, premixed insulin, glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), dipeptidyl peptidase 4 inhibitors, sodium-glucose cotransporter 2 inhibitors, and α-glucosidase inhibitors. Other approaches, such as combinations of newer basal insulin plus RAI and a fixed-ratio combination of basal insulin and a GLP-1 RA, are also described.

show abstract

Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: The ASSIST-K study

Cited by 13 publications

References 10 publications

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study

Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study

A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once‐daily injection in patients with well‐controlled type 2 diabetes

Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies

Contact Info

Product

Resources

About